instruction:
Generate an explanation for the given claim using the provided supporting material from the paragraph. Please consider the following points while generating an output. 1) The claim will always have supporting proof in the paragraph, and the paragraph will have a clear point of view supporting the claim. 2) There can be instances where direct correlation to the claim is not available. Make use of the sentences in the paragraph to provide a corresponding output supporting the claim. 3) The explanation should be at least one and at most twelve sentences long.
question:
Paragraph: Chief Executive Andrew Witty said on Wednesday there were still “intriguing” opportunities for its heart drug darapladib and MAGE-A3 therapeutic cancer vaccine. Many analysts stripped out forecasts for darapladib, which is designed to prevent heart attacks and strokes in a completely different way from cholesterol-lowering drugs, after it failed to reduce risks in the first of two big final Phase III trials in November. GSK, however, is continuing to investigate the drug’s role in coronary heart disease and Witty told analysts in a call following full-year results that further data on the approach would be presented at a medical meeting next month. He was also upbeat about prospects for the MAGE-A3 cancer vaccine in other tumor settings, despite initial negative results in melanoma in September. Unlike traditional preventative vaccines, MAGE-A3 is designed for people with established disease, helping their immune systems to prevent the return of tumors after surgery. In fact the head of Britain’s biggest drugmaker said both darapladib and MAGE-3 were among the most promising drugs in the company’s pipeline. He also highlighted a new triple combination respiratory drug, a long-acting integrase inhibitor for HIV and a drug for pre-term labor, all of which could start final Phase III clinical testing this year or next. Claim: GSK upbeat on heart drug, cancer vaccine despite setbacks.
answer:
Two high-risk bets by GlaxoSmithKline on new ways to fight heart disease and cancer were dealt a double blow last year by dud clinical trials - but the company remains hopeful about both projects.


question:
Paragraph: Interior minister Sajid Javid used an exceptional power on Saturday to release medicinal cannabis oil that had been taken from Billy Caldwell, 12, by customs officials at London’s Heathrow Airport. Billy’s mother, Charlotte Caldwell, had been pleading for the medication to be given back because without it her son suffered from life-threatening seizures. “This case .. has shone a light on the use of cannabis medicine in this country and highlighted the need for the government to explore the issue further, and our handling of these issues further,” said Nick Hurd, a junior minister in charge of policing. “As a first step, I can announce today that the government is establishing an expert panel of clinicians to advise ministers on any individual applications to prescribe cannabis-based medicines,” he told parliament. Under British law, cannabis is listed as a schedule 1 drug, meaning that it is not recognized as having a therapeutic value. Schedule 1 drugs can be used for research purposes and clinical trials but only under a Home Office license. “I recognize the need to ensure that the approach to licensing works more effectively,” Hurd said. Billy Caldwell had been receiving medicinal cannabis oil on prescription by his family doctor for more than a year, but supplies ran out after the interior ministry ordered the doctor to stop prescribing it. Charlotte Caldwell and her son, who normally live in Northern Ireland, made a round trip to Canada to buy more supplies, but the oil was confiscated by customs when they re-entered Britain. Billy was hospitalized days later, suffering from seizures. His condition improved after the medicinal cannabis oil was handed back and on Monday he was discharged from hospital. Several members of parliament from different parties voiced support for the Caldwell family and to the idea of loosening the rules on therapeutic uses of cannabis in responses to Hurd’s statement on Monday. Claim: UK signals changes on medicinal cannabis use after epileptic boy's case.
answer:
The British government will look into possible changes to rules on the use of cannabis-based medicines, a minister said on Monday, after an epileptic boy whose medication was confiscated was hospitalized.


question:
Paragraph: The French drugmaker said it was working with health authorities to determine the level and extent of the recall, which it called a precautionary measure being taken due to possible contamination with a substance called N-nitrosodimethylamine (NDMA). Sanofi has sold over-the-counter Zantac in the U.S. and Canada since 2017. It is pulling the drug off shelves after previous recalls by some manufacturers of generic versions of the drug. Sanofi reported Zantac sales of 127 million euros in 2018 69 million euros over the first half of 2019. U.S. and European health regulators said last month they were reviewing the safety of ranitidine, which is commonly sold as Zantac and its generic alternatives, after an online pharmacy called Valisure notified them that it had found impurities in the drugs. The U.S. Food and Drug Administration said earlier this month it found unacceptable levels of NDMA in drugs containing ranitidine. The regulator asked ranitidine makers to conduct their own testing to assess levels of the impurity and to send samples of their products for testing by the agency. Canada has requested drugmakers halt distribution of the drug while it gathers more information. Sanofi CEO Paul Hudson, speaking at a press conference in Framingham, Mass., earlier this week, downplayed concerns about the drug. “We don’t believe there’s a risk,” Hudson said on Tuesday. “But we have to - and are appropriately duty bound to - satisfy the regulators, which we will do, and we’ll move on from there.”  Other drugmakers including GlaxoSmithKline and  Novartis have recalled or halted distribution of their versions of the drug. Retailers and pharmacy chains including Walmart Inc CVS Health Corp, Walgreens Boots Alliance Inc and Rite Aid Corp have suspended the sale of drugs containing ranitidine. The FDA has said it does not have enough scientific evidence yet to determine how long NDMA has been present in ranitidine. But Valisure - the online pharmacy that flagged the issue to regulators - believes the problem is inherent to the drug itself and NDMA may have been present as long as its been on the market. Ranitidine is the latest drug in which cancer-causing impurities have been found. Regulators have been recalling some blood pressure and heart failure medicines since last year. Claim: Sanofi pulls Zantac from U.S. and Canada after carcinogen found.
answer:

Sanofi SA said on Friday it would recall popular heartburn medicine Zantac in the United States and Canada, after the medicines were linked with a probable cancer-causing impurity.